Company news

Share this article:
Teva Pharmaceuticals has announced the completion of its acquisition of Barr Pharmaceuticals, for $7.46 billion, plus the assumption of roughly $1.5 billion in debt. Barr's generic business in the US will extend Teva's product portfolio, while adding a substantial women's healthcare business, among other things, said Shlomo Yanai, Teva president and CEO, in a statement.

A US district court in California has dismissed a lawsuit against Amgen that claimed the company had promoted two anemia drugs – Epogen and Aranesp – off-label. The court said government regulators, and not private companies or individuals, had the right to bring such an action. The lawsuit was filed as a class action suit, involving claims made by seven health benefit plan providers.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.